ATE411015T1 - USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENES AS PEPTIDES IN AMYLOID PATHIES - Google Patents

USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENES AS PEPTIDES IN AMYLOID PATHIES

Info

Publication number
ATE411015T1
ATE411015T1 AT04821452T AT04821452T ATE411015T1 AT E411015 T1 ATE411015 T1 AT E411015T1 AT 04821452 T AT04821452 T AT 04821452T AT 04821452 T AT04821452 T AT 04821452T AT E411015 T1 ATE411015 T1 AT E411015T1
Authority
AT
Austria
Prior art keywords
fibrillogenes
pathies
amyloid
peptides
aminocyclohexane derivatives
Prior art date
Application number
AT04821452T
Other languages
German (de)
Inventor
Sandeep Gupta
Pradeep Banarjee
Debomoy Lahiri
Martin Farlow
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34885905&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE411015(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Application granted granted Critical
Publication of ATE411015T1 publication Critical patent/ATE411015T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT04821452T 2003-10-22 2004-10-22 USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENES AS PEPTIDES IN AMYLOID PATHIES ATE411015T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51370003P 2003-10-22 2003-10-22

Publications (1)

Publication Number Publication Date
ATE411015T1 true ATE411015T1 (en) 2008-10-15

Family

ID=34885905

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04821452T ATE411015T1 (en) 2003-10-22 2004-10-22 USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENES AS PEPTIDES IN AMYLOID PATHIES

Country Status (13)

Country Link
US (1) US20050113458A1 (en)
EP (1) EP1682109B1 (en)
JP (1) JP2007509165A (en)
CN (1) CN1870984A (en)
AR (1) AR046601A1 (en)
AT (1) ATE411015T1 (en)
AU (1) AU2004316119B2 (en)
CA (1) CA2540921A1 (en)
DE (1) DE602004017207D1 (en)
IL (1) IL174970A0 (en)
TW (1) TW200526194A (en)
WO (1) WO2005079779A1 (en)
ZA (1) ZA200603231B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US20090227647A1 (en) * 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (en) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Methods and compositions for the treatment of CNS related diseases
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
RU2326660C1 (en) * 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Oral pharmaceutical composition memantin (options) and method of preparation (options)
JP5667440B2 (en) 2007-04-18 2015-02-12 プロビオドルグ エージー Thiourea derivatives as glutaminyl cyclase inhibitors
US20090118376A1 (en) * 2007-11-02 2009-05-07 Ru-Band Lu Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia
ES2341517B1 (en) * 2008-03-28 2011-01-25 Farmalider, S.A USE OF AN INHIBITOR COMPOUND OF THE ACTIVATION OF THE ERK 1/2 ENZYME IN THE TREATMENT OF NEURODEGENERATIVE DISEASES.
MX2012002993A (en) 2009-09-11 2012-04-19 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase.
US20110236917A1 (en) * 2009-11-17 2011-09-29 Power3 Medical Products, Inc. Diagnosis of Alzheimer's Disease
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
MX2012010470A (en) 2010-03-10 2012-10-09 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
PL2578212T3 (en) 2010-05-24 2017-01-31 Farmalider Sa Compound inhibiting activation of the enzyme erk1/2 for use in the treatment of neurogenerative illnesses
WO2012068161A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN108026107B (en) 2015-06-19 2021-07-30 艾吉因生物股份有限公司 Benzodiazepine derivatives, compositions and methods for treating cognitive impairment
EP3474831A1 (en) 2016-06-23 2019-05-01 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
WO2018022814A1 (en) 2016-07-27 2018-02-01 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
MX2019001104A (en) 2016-07-27 2019-10-02 Corium Int Inc Memantine transdermal delivery systems.
KR20230109782A (en) 2016-07-27 2023-07-20 코리움, 엘엘씨 Sodium bicarbonate in situ conversion driven transdermal delivery of amine drug
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (en) 2016-12-19 2019-11-26 Agenebio Inc benzodiazepine derivatives, compositions and methods for the treatment of cognitive impairment
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. Enantiomerically pure adamantane derivatives for the treatment of filovirus infection
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
CA3104478A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CH603545A5 (en) * 1972-04-20 1978-08-31 Merz & Co
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
DE2856393C2 (en) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Medicines used to treat Parkinson's disease
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4503030A (en) * 1983-06-06 1985-03-05 Alza Corporation Device for delivering drug to certain pH environments
US4615698A (en) * 1984-03-23 1986-10-07 Alza Corporation Total agent osmotic delivery system
US4737456A (en) * 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4849222A (en) * 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (en) * 1988-02-24 1997-10-29 株式会社ビーエムジー Polylactic acid microspheres containing physiologically active substance and method for producing the same
ATE94384T1 (en) * 1989-04-14 1993-10-15 Merz & Co Gmbh & Co USE OF ADAMANTAN DERIVATIVES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCHAEMIA.
US5912410A (en) * 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
CA2292558C (en) * 1997-06-30 2006-09-19 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane nmda receptor antagonists
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
TW200410672A (en) * 2002-07-19 2004-07-01 Merz Pharma Gmbh & Co Kgaa NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
MXPA04006900A (en) * 2002-10-24 2004-10-15 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors.

Also Published As

Publication number Publication date
IL174970A0 (en) 2006-08-20
JP2007509165A (en) 2007-04-12
ZA200603231B (en) 2007-11-28
WO2005079779A1 (en) 2005-09-01
AR046601A1 (en) 2005-12-14
DE602004017207D1 (en) 2008-11-27
EP1682109B1 (en) 2008-10-15
AU2004316119A1 (en) 2005-09-01
TW200526194A (en) 2005-08-16
US20050113458A1 (en) 2005-05-26
EP1682109A1 (en) 2006-07-26
AU2004316119B2 (en) 2008-04-24
CN1870984A (en) 2006-11-29
CA2540921A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
ATE411015T1 (en) USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENES AS PEPTIDES IN AMYLOID PATHIES
DE60334277D1 (en) Use of algae proteins in cosmetics
IL176781A0 (en) Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
DE602005012555D1 (en) Artificial protein for the absolute quantification of proteins and uses thereof
DE60326874D1 (en) NEW USE OF ERYTHROPOIETIN IN HEART DISEASES
DE602005014922D1 (en) Linearity corrector with multiplication of filters
ATE524183T1 (en) USE OF SANGLIFEHRIN IN HCV THERAPY
EP1791855A4 (en) Methods and compositions related to argonaute proteins
DE60304223D1 (en) PREPARATION OF METALAMIDE COMPLEXES
DE10390418D2 (en) Process for the production of recombinant proteins in microorganisms
IS8338A (en) Production of somatostatin peptides
DE60322898D1 (en) USE OF ISOFLAVONES TO PROMOTE SLIMMING EFFECT
DE602004023786D1 (en) Production of high purity alkylgallium
DE50311406D1 (en) Use of moldings
DE602004010307D1 (en) USE OF POLYSULPATED ALGINATE IN CELL MATRIX
DE50304051D1 (en) USE OF PLASTIC FOILS AS DIELEKTRIKUM IN CAPACITORS
DE602004022046D1 (en) PREPARATION OF SMALL PARTICLES
ATE505484T1 (en) TRIMER PROTEINS TO TRIMER CYTOKINE
ITMI20041440A1 (en) ANALOGUE PEPTIDES OF PTH-1-11
IL165484A0 (en) Production of proteins
DE602004005408D1 (en) Tire with internal coating to prevent vapor permeability
FI20040655A (en) Protein and peptide stabilization
NO20031818D0 (en) Process of bioactive peptide preparation
DE602004022136D1 (en) LEUKOCYTES STIMULATING PEPTIDES
EP1732615A4 (en) Production of peptides in plants as viral coat protein fusion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties